Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Biohaven Pharmaceutical Holding Company Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SK BIOPHARMACEUTICALS TO PROVIDE UPFRONT AND MILESTONE PAYMENTS RELATED TO THE KV7 PLATFORM UP TO $795 MILLION, ALONG WITH TIERED ROYALTIES TO BIOHAVEN RANGING FROM THE MID-TEENS TO LOW TWENTIES ON U.S. NET SALES OF OPAKALIM. OPAKALIM, THE LEAD CANDIDATE FROM BIOHAVEN'S KV7 PLATFORM, IS A NEXT-GENERATION, SELECTIVE KV7.2/7.3 POTASSIUM CHANNEL ACTIVATOR CURRENTLY IN PHASE 2/3 DEVELOPMENT FOR FOCAL EPILEPSY, WITH TOPLINE RESULTS FROM THE RISE3 TRIAL EXPECTED IN 2H 2026.

BIOHAVEN AND SK BIOPHARMACEUTICALS ENTER INTO STRATEGIC GLOBAL LICENSING AGREEMENT FOR NOVEL KV7 ION CHANNEL PLATFORM AND OPAKALIM, LEAD CANDIDATE FOR EPILEPSY

NEW HAVEN, CONN., AUG. 25, 2026 /PRNEWSWIRE/ --BIOHAVEN LTD.

FEDERAL COURT ENTERS JUDGMENT CONFIRMING RA CAPITAL AND AVILAR THERAPEUTICS WILLFULLY AND MALICIOUSLY MISAPPROPRIATED TRADE SECRET DEVELOPED AT YALE, FORMALIZING $4 MILLION AWARD TO BIOHAVEN AND YALE UNIVERSITY

FIRST EXTRACELLULAR PROTEIN DEGRADERS IN THE CLINIC DEMONSTRATE RAPID AND ROBUST PHARMACODYNAMIC EFFECTS AND COMPELLING SAFETY IN NEARLY 200 INDIVIDUALS DOSED, PHASE 3 TRIAL UNDERWAY POSITIVE CLINICAL BIOMARKER AND PATIENT DATA PRESENTED FROM BIOHAVEN'S EXTRACELLULAR DEGRADER PLATFORM DEMONSTRATED DEEP, RAPID, SELECTIVE LOWERING OF DISEASE-DRIVING ANTIBODIES WITH BHV-1300 IN GRAVES' DISEASE AND BHV-1400 IGA NEPHROPATHY, SUPPORTING ADVANCEMENT TOWARD MULTIPLE REGISTRATIONAL PROGRAMS. INITIATED PIVOTAL PHASE 3 STUDY FOR BHV-1300 IN GRAVES' DISEASE WITH PLANS TO INITIATE PIVOTAL PHASE 3 STUDY FOR BHV-1400 IN IGAN IN 2H 2026.

BIOHAVEN REPORTS RECENT BUSINESS DEVELOPMENTS AND SECOND QUARTER 2026 FINANCIAL RESULTS

INFINITUM FOUNDER AND GROQ BOARD DIRECTOR BRINGS FRONTIER AI AND TECHNOLOGY-INVESTING EXPERTISE TOBIOHAVEN AS THE COMPANY ADVANCES AI-ENABLED APPROACHES TO DRUG DEVELOPMENT NEW HAVEN, CONN., AUG. 6, 2026 /PRNEWSWIRE/ -- BIOHAVEN LTD.

BIOHAVEN APPOINTS TECHNOLOGY INVESTOR JOHN YETIMOGLU TO BOARD OF DIRECTORS

NEW HAVEN, CONN., JULY 27, 2026 /PRNEWSWIRE/ -- BIOHAVEN LTD.

FEDERAL JURY FINDS AVILAR THERAPEUTICS AND RA CAPITAL WILLFULLY AND MALICIOUSLY MISAPPROPRIATED TRADE SECRET DEVELOPED AT YALE, AWARDS BIOHAVEN AND YALE UNIVERSITY $4 MILLION

BIOHAVEN ALSO ANNOUNCES NEW CLINICAL SUPPLY AGREEMENT WITH REGENERON TO EVALUATE BHV-1530 IN COMBINATION WITH CEMIPLIMAB (LIBTAYO) EARLY CLINICAL ACTIVITY OBSERVED: PHASE 1 DOSE-ESCALATION DATA SHOW EARLY TUMOR REDUCTIONS IN PATIENTS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR)3-ALTERED AND WILD-TYPE OVEREXPRESSING TUMORS. SIGNAL ACTIVITY INCLUDING CONFIRMED PARTIAL RESPONSES IN HEAVILY PRETREATED PATIENTS IN MULTIPLE TUMOR TYPES.

BIOHAVEN TO PRESENT NEW CLINICAL DATA AT ESMO CONGRESS ON BHV-1530, A NOVEL FGFR3-DIRECTED ADC WITH A PROPRIETARY TOPOISOMERASE I (TOPOIX) PAYLOAD

DAVID PIRMAN, PH.D. PROMOTED TO EXECUTIVE VICE PRESIDENT AND HEAD OF DISCOVERY BRUCE CAR, PH.D.

BIOHAVEN ANNOUNCES SCIENTIFIC LEADERSHIP TRANSITIONS

ENROLLMENT COMPLETE IN PIVOTAL PHASE 2/3 STUDY EVALUATING OPAKALIM IN FOCAL EPILEPSY (RISE3); TOP-LINE RESULTS ON TRACK FOR 2H 2026 EMERGING OPAKALIM FOCAL EPILEPSY AND IDIOPATHIC GENERALIZED EPILEPSY DATA PRESENTED AT RECENT R&D DAY REINFORCE EVIDENCE OF TARGET ENGAGEMENT, POTENTIAL FOR EFFICACY, AND DIFFERENTIATED TOLERABILITY PROFILE IN THE ONGOING FOCAL EPILEPSY OPEN-LABEL EXTENSION (OLE) STUDY, 54% OF PARTICIPANTS ON OPAKALIM 75 MG ONCE-DAILY ACHIEVED A 50% REDUCTION IN SEIZURE FREQUENCY COMPARED TO PRE-RANDOMIZATION BASELINE, WITH A MARKEDLY LOWER INCIDENCE OF NERVOUS SYSTEM ADVERSE EVENTS COMPARED TO APPROVED AND INVESTIGATIONAL ASMS HIGH DOUBLE-BLIND COMPLETION RATES OF ~95%, AND HIGH ROLLOVER RATES INTO THE OLE OF ~95%, REFLECT FAVORABLE PATIENT EXPERIENCE WITH OPAKALIM NEW HAVEN, CONN., JUNE 30, 2026 /PRNEWSWIRE/ -- BIOHAVEN LTD.

BIOHAVEN COMPLETES ENROLLMENT IN RISE 3 PIVOTAL FOCAL EPILEPSY STUDY WITH OPAKALIM, A SELECTIVE KV7.2/7.3 ACTIVATOR

BHV-1300 IS THE FIRST MODE EXTRACELLULAR PROTEIN DEGRADER TO ENTER A PIVOTAL TRIAL, PIONEERING A NEW CLASS OF PRECISION IMMUNOLOGY MEDICINES THAT ELIMINATE THE DISEASE-DRIVING ANTIBODIES AT THE ROOT OF AUTOIMMUNE DISEASE. BHV-1300 TARGETS THE TSHR-IGG1 AUTOANTIBODY THAT DRIVES GRAVES' DISEASE, NOT THE THYROID GLAND ITSELF.

BIOHAVEN ADVANCES A NEW CLASS OF PRECISION IMMUNOLOGY THERAPIES: FIRST MODE EXTRACELLULAR PROTEIN DEGRADER, BHV-1300, BEGINS PHASE 3 PIVOTAL TRIAL IN GRAVES' DISEASE

BHV-8100 IS AN ORALLY ADMINISTERED, BRAIN-PENETRANT PKM2 MODULATOR; A NOVEL THERAPEUTIC CLASS ADDRESSING THE BIOENERGETIC AND IMMUNOMETABOLIC BASIS OF SYSTEMIC AND CENTRAL NERVOUS SYSTEM DISORDERS FIRST-IN-HUMAN STUDY INITIATED WITH DOSE ESCALATION ONGOING; PRELIMINARY DATA IN HEALTHY PARTICIPANTS DEMONSTRATES FAVORABLE PHARMACOKINETICS SUPPORTING CONVENIENT, ONCE-DAILY DOSING AND WELL A TOLERATED PROFILE AT PROJECTED THERAPEUTIC EXPOSURES PENETRATES BLOOD-BRAIN BARRIER AND REVERSES METABOLIC DYSFUNCTION WITH 3-FOLD IMPROVEMENT IN GLUCOSE UTILIZATION IN HUMAN, WHOLE BRAIN MODEL (BEXORG BRAINEX PLATFORM, PHYSIOLOGICALLY REACTIVATED BRAINS FROM HUMAN DONORS); PREFERENTIAL METABOLIC RESCUE IN ALZHEIMER'S DISEASE DONOR BRAINS VS CONTROLS EXHIBITS ROBUST BENEFICIAL EFFECTS ACROSS A SPECTRUM OF PRECLINICAL MODELS OF ALZHEIMER'S, AND MULTIPLE SCLEROSIS: RESTORES METABOLIC DEFICITS, REDUCES INFLAMMATION AND NEURODEGENERATION, AND ENHANCES REMYELINATION PKM2 MODULATION OFFERS A POTENTIAL NEW PARADIGM FOR TREATING LARGE, UNDERSERVED, AND HIGH-VALUE INDICATIONS IN NEUROLOGY, OPHTHALMOLOGY, AND IMMUNOLOGY NEW HAVEN, CONN., JUNE 1, 2026 /PRNEWSWIRE/ --BIOHAVEN LTD.

Biohaven Pharmaceutical Holding Company Ltd.

BHVN

Price

Financial Reports

No items found.

Press Releases

Biohaven Pharmaceutical Holding Company Ltd.

BHVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BHVN